0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Conferences |

Lung Cancer: Perspectives and Prospects

PAUL P. CARBONE, M.D.; JOHN K. FROST, M.D.; ALVAN R. FEINSTEIN, M.D.; GEORGE A. HIGGINS JR., M.D.; and OLEG S. SELAWRY, M.D.
[+] Article and Author Information

Dr. H. H. Hansen, Senior Cancer Research Internist, NCI-VA Medical Oncology Service, and Dr. S. Carter, Head, Cancer Therapy Evaluation Branch, NCI, contributed substantially to the review of literature.

▸Requests for reprints should be addressed to Paul P. Carbone, M.D., Chief, Medicine Branch, National Cancer Institute, Bldg. 10, Rm. 2-B-46, National Institutes of Health, Bethesda, Md. 20014


Bethesda, Maryland; New Haven, Connecticut; and Washington, D.C.


Ann Intern Med. 1970;73(6):1003-1024. doi:10.7326/0003-4819-73-6-1003
Text Size: A A A

Lung cancer offers a challenge for earlier diagnosis and better treatment results. At present lung cancer is recognized late. Opportunities to improve survival are through early detection, accurate diagnosis, absolute localization, and curative therapy. Improvements in diagnosis are being developed, including the fibro-optic bronchoscope. The biology of lung cancer is reflected by its morphological characteristics and clinical symptoms. A clinicoanatomic scheme permits prediction of survival. Surgical treatment remains the only definitive cure. A large study (VA Surgical Adjuvant Group) has indicated no improvement in survival with short-term adjuvant chemotherapy or preoperative X-ray therapy At present treatment with intermittent long-term therapy is administered in hopes of decreasing recurrence rates. The VA Lung Cancer Medical Group has shown improved survival with mechlorethamine in squamous cell carcinoma and cyclophosphamide in oat cell carcinoma. Future advances would include use of combinations of drugs. Prospects for patients should improve soon because of leads presented in this conference.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)